pertuzumab

Dec 26, 2025

The pharmaceutical landscape for HER2-positive metastatic breast cancer has undergone a significant transformation with the FDA's approval of ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab as a first-line treatment—marking the first new therapeutic option approved in more than a decade for...

Aug 13, 2024

For most of the last century, breast cancer was categorized only by its location in the body; as a result, treatment results varied significantly. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. In September 1998, th...